BGLC BioNexus Gene Lab Corp
Updated
Healthcare · Services-Medical Laboratories
BioNexus Gene Lab Corp (BGLC) is a healthcare company in the Services-Medical Laboratories industry, with a market capitalization of $4 million. Shares last traded at $1.40, 93.9% below their 52-week high. Over the past year the stock is down 49.8%. Net profit margin is -34.7%, below the peer median of -5.4%. Revenue declined 21.9% year over year.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $-0.34 | 2026-08-14 |
| Q1 2026 | $-0.23 | 2026-05-15 |
| Q3 2025 | $-1.08 | 2025-11-14 |
| Q2 2026 | $-0.69 | 2026-08-14 |
| Q1 2026 | $-0.35 | 2026-05-15 |
| FY 2024 | $-0.09 | 2025-04-15 |
Services-Medical Laboratories peers
BGLC vs 14 industry peers (Services-Medical Laboratories), by market cap. Updated
| NTRA | Natera, Inc. | $47.2B | -245.26 | 17.43 | -7.1% | +0.66% |
| LH | Labcorp | $26.9B | 26.82 | 1.87 | 7.0% | -0.07% |
| DGX | Quest Diagnostics | $26.4B | 24.88 | 2.29 | 9.2% | -0.58% |
| GH | Guardant Health, Inc. | $21.6B | -47.65 | 18.26 | -38.3% | -1.23% |
| CAI | Caris Life Sciences, Inc. | $7.2B | 68.06 | 7.23 | 10.6% | +2.14% |
| RDNT | Radnet, Inc. | $5.9B | -278.18 | 2.59 | -0.9% | -1.36% |
| CELC | Celcuity Inc. | $4.7B | -20.82 | — | — | +0.06% |
| BLLN | Billiontoone, Inc. | $4.6B | 121.86 | 11.56 | 9.5% | +3.64% |
| GRAL | Grail, Inc. | $3.6B | -9.19 | — | — | +0.03% |
| VCYT | Veracyte, Inc. | $3.6B | 31.35 | 6.39 | 20.4% | -0.65% |
| CDNA | Caredx, Inc. | $2.6B | 23.22 | 5.63 | 24.2% | +0.44% |
| PSNL | Personalis, Inc. | $1.8B | -16.77 | — | — | +0.51% |
| FTRE | Fortrea Holdings Inc. | $1.8B | -20.77 | 0.66 | -3.2% | +1.47% |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | — | — | — | -1.53% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.